CRLF3 Human shRNA Lentiviral Particle (Locus ID 51379)
CAT#: TL305215V
CRLF3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
Cited in 1 publication. |
CNY 2,950.00
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | CRLF3 Human shRNA Lentiviral Particle (Locus ID 51379) |
Locus ID | 51379 |
Synonyms | CREME-9; CREME9; CRLM9; CYTOR4; FRWS; p48.2 |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_015986, NR_073118, NM_015986.1, NM_015986.2, NM_015986.3, BC023567, NM_015986.4 |
Summary | This gene encodes a cytokine receptor-like factor that may negatively regulate cell cycle progression at the G0/G1 phase. Studies of the related rat protein suggest that it may regulate neuronal morphology and synaptic vesicle biogenesis. This gene is one of several genes located in the neurofibromatosis type I tumor suppressor region on the q arm of chromosome 17, a region that is subject to microdeletions, duplications, chromosomal breaks and rearrangements. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 2 and 5. [provided by RefSeq, Aug 2012] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis
,null,
Cell reports
,PubMed ID 34233200
[CRLF3]
|
Documents
Product Manuals |
FAQs |
SDS |